News & Analysis on Clinical Trial Services & Contract Research And Development
Phastar: investment by Charterhouse Capital Partners
By Jenni Spinner
- Last updated on
Speciality CRO Phastar has joined forces with and received funding from Charterhouse Capital Partners, a European private equity firm. The funding will be used to fuel the CRO’s growth in biometrics as well as plans for geographic expansion.
“Phastar’s partnership with Charterhouse is a significant next step in our planned growth strategy,” said Phastar CEO Kevin Kane. “With a new office opening in China our global footprint will widen to include the UK, Europe, Africa, the US and Asia, giving us an opportunity to better serve our clients anywhere in the world.”